{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:55Z","timestamp":1790516155199,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":311,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.ctarc.2020.100236","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T13:18:53Z","timestamp":1604927933000},"page":"100236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A population-based study of hairy cell leukemia over a period of 20 years"],"prefix":"10.1016","volume":"25","author":[{"given":"Margaux","family":"Wiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Duchenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2020.100236_bib0001","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.hoc.2006.06.012","article-title":"Immunophenotyping and Differential Diagnosis of Hairy Cell Leukemia","volume":"20","author":"Matutes","year":"2006","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctarc.2020.100236_bib0002","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF Mutations in Hairy-Cell Leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2020.100236_bib0003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia, N","volume":"310","author":"Quesada","year":"1984","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.ctarc.2020.100236_bib0004","first-page":"1336","article-title":"induction of complete remission with pentostatin (2\u2019-deoxycoformycin), J","volume":"2","author":"Spiers","year":"1984","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100236_bib0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine, N","volume":"322","author":"Piro","year":"1990","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.ctarc.2020.100236_bib0006","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ajh.24936","article-title":"cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment","volume":"92","author":"Troussard","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctarc.2020.100236_bib0007","first-page":"3605","article-title":"Epidemiology of Hairy Cell Leukemia in Los Angeles County","volume":"50","author":"Bernstein","year":"1990","journal-title":"Cancer research"},{"key":"10.1016\/j.ctarc.2020.100236_bib0008","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2017-12-820381","article-title":"Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands","volume":"131","author":"Dinmohamed","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0009","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2006.00732.x","article-title":"A population-based study of hairy cell leukemia in Israel","volume":"77","author":"Paltiel","year":"2006","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.ctarc.2020.100236_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djk030","article-title":"Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study, J","volume":"99","author":"Hisada","year":"2007","journal-title":"Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2020.100236_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bjh.12490","article-title":"Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors","volume":"163","author":"Chandran","year":"2013","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.ctarc.2020.100236_bib0012","first-page":"A4216","article-title":"Incidence, risk of infection and survival of hairy cell leukaemia in Denmark","volume":"57","author":"Teodorescu","year":"2010","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.ctarc.2020.100236_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.thj.6200167","article-title":"Epidemiology of hairy cell leukemia in Iceland","volume":"3","author":"Kristinsson","year":"2002","journal-title":"Hematol. J"},{"key":"10.1016\/j.ctarc.2020.100236_bib0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0015","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00277-014-2140-y","article-title":"French Society of Haematology, Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia","volume":"93","author":"Cornet","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctarc.2020.100236_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1521-6926(02)00085-3","article-title":"Clinical manifestations and infectious complications of hairy-cell leukaemia","volume":"16","author":"Kraut","year":"2003","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"10.1016\/j.ctarc.2020.100236_bib0017","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34\u2013expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0018","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0019","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.21873\/anticanres.13003","article-title":"Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel","volume":"38","author":"Inbar","year":"2018","journal-title":"Anticancer Research"},{"key":"10.1016\/j.ctarc.2020.100236_bib0020","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190600555819","article-title":"Sex differences in incidence and outcome of chronic lymphocytic leukemia patients","volume":"47","author":"Molica","year":"2006","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.ctarc.2020.100236_bib0021","first-page":"5","article-title":"Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy","author":"Horesh","year":"2014","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.ctarc.2020.100236_bib0022","first-page":"1803","article-title":"Second cancer risk in hairy cell leukemia: analysis of 350 patients, J","volume":"15","author":"Kurzrock","year":"1997","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100236_bib0023","first-page":"638","article-title":"Italian Cooperative Group for the Study of Hairy Cell Leukemia, Risk of second cancer in patients with hairy cell leukemia: long-term follow-up, J","volume":"20","author":"Federico","year":"2002","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100236_bib0024","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.V83.10.2931.2931","article-title":"Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment","volume":"83","author":"Kampmeier","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/10428199609051735","article-title":"Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha","volume":"22","author":"Pawson","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ctarc.2020.100236_bib0026","first-page":"2454","article-title":"Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias, J","volume":"17","author":"Cheson","year":"1999","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100236_bib0027","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0028","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/1097-0142(19850915)56:6<1462::AID-CNCR2820560639>3.0.CO;2-6","article-title":"Second malignancies in hairy cell leukemia","volume":"56","author":"Jacobs","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2020.100236_bib0029","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.V92.4.1160","article-title":"Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience","volume":"92","author":"Au","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0030","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0031","first-page":"891","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine, J","volume":"21","author":"Goodman","year":"2003","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100236_bib0032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients","volume":"17","author":"Maloisel","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2020.100236_bib0033","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood.V84.9.3242.3242","article-title":"Second cancer risk after interferon therapy?","volume":"84","author":"Troussard","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2020.100236_bib0034","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/bjh.15777","article-title":"Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia","volume":"185","author":"Zheng","year":"2019","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.ctarc.2020.100236_bib0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjh.12908","article-title":"the Soci\u00e9t\u00e9 Fran\u00e7aise d'H\u00e9matologie, Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia","volume":"166","author":"Cornet","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.ctarc.2020.100236_bib0036","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.0007-1048.2001.03318.x","article-title":"Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia","volume":"116","author":"Bourguin-Plonquet","year":"2002","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.ctarc.2020.100236_bib0037","article-title":"Defective interferon-gamma production in patients with hairy cell leukaemia","volume":"66","author":"Netea","year":"2008","journal-title":"Neth J Med"},{"key":"10.1016\/j.ctarc.2020.100236_bib0038","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/10428199309148536","article-title":"Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia","volume":"9","author":"Bigda","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ctarc.2020.100236_bib0039","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1006\/clim.1999.4794","article-title":"Impaired expression of CD28 on T cells in hairy cell leukemia","volume":"93","author":"van de Corput","year":"1999","journal-title":"Clin. Immunol"},{"key":"10.1016\/j.ctarc.2020.100236_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.06.001","article-title":"Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort","volume":"83","author":"da Silva","year":"2019","journal-title":"Leukemia Research"},{"key":"10.1016\/j.ctarc.2020.100236_bib0041","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bjh.13528","article-title":"Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center","volume":"171","author":"Watts","year":"2015","journal-title":"Br J Haematol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422030071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422030071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:24:58Z","timestamp":1762842298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422030071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":41,"alternative-id":["S246829422030071X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100236","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A population-based study of hairy cell leukemia over a period of 20 years","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100236"}}